(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
Furthermore, the company's order backlog has steadily increased throughout the year and is at a record level, which holds promise for the year ahead. We upgrade our recommendation from Neutral to Outperform and set a target price of
We downgrade our recommendation on NII Holdings, Inc. (Nasdaq: NIHD) to Underperform backed by our assessment that the company s nightmare will continue in the near future. NII Holdings reported dismal financial results for the third quarter of 2011. Both the top line and bottom line were well below the Zacks Consensus Estimates.
Management has slashed its fiscal 2011 financial outlook, mainly driven by the volatile macro-economic condition coupled with significant depreciation of several Latin American currencies in comparison with U.S. dollars. Moreover, stiff competitive scenarios in Latin American markets are other impediments for such a reduced outlook.
We believe intensifying competition and increased promotional expenses may reduce the company's near-term growth opportunities. We do not find any immediate catalysts and expect NII Holdings to report weak financial results for the company's 4th quarter.
Latest Posts on the Zacks Analyst Blog:
Lowe's Balancing Act
The growth of home improvement companies is directly proportional to the housing market cycles, which in turn is closely related with the prevailing economic conditions. A tremor at one end obviously makes its rippling effects evident on the other end too.
Remember the subprime crisis, which destabilized the U.S. housing market? Thus
A Look at Guidance
Lowe's expects fourth-quarter 2011 earnings in the range of
Management now expects sales to increase approximately 8% in the fourth quarter and between 2% and 3% in fiscal 2011. Earlier, Lowe's had forecasted fiscal 2011 sales to increase by approximately 2%. Lowe's expects comparable-store sales to remain flat or up 1% in the fourth quarter but to decline by 1% in fiscal 2011.
Challenging Economy & Competition
Heavy job losses and reduced access to credit have lead to a sharp fall in consumer discretionary spending on big-ticket items. With the global economic environment still struggling, we believe that spending on big remodeling projects will likely remain under pressure until the housing market stabilizes and consumer-spending rebounds.
Lowe's in the home improvement retailing business faces stiff competition from
St. Just Halts FAME II Enrollment
Medical devices majorSt.Jude Medical (NYSE: STJ) will stop enrolling new patients in its FAME II clinical trial following positive results from an interim analysis.
The independent data safety monitoring board ("DSMB") recommended investigators to halt patient enrollment in the study following the impressive results which have shown statistically significant reduction in the need for hospital readmission and urgent revascularization when fractional flow reserve ("FFR")-guided assessment is used in treating patients with coronary artery disease.
FFR is an index that identifies and measures the severity of coronary artery narrowing. It specifically locates the coronary narrowings which are responsible for occluding blood flow to a patient's heart muscle and directs the surgeons to identify the lesions requiring stenting. The approach is believed to help rein in healthcare costs and improve patient outcome.
The company-sponsored FAME II trial is evaluating the use of St. Jude's PressureWire FFR devices during the treatment of patient with stable coronary artery disease. The objective of the trial is to study the role of FFR in treating this condition by comparing FFR-guided percutaneous coronary intervention ("PCI") plus optimal medical therapy ("OMT") with OMT alone.
The DSMB considered it unethical to continue randomize patients to OMT alone as patients experienced a highly statistically significant increased risk of hospital readmission and urgent revascularization. The DSMB advised St. Jude to stop enrolling patients in the FAME II study given the higher risk of major adverse cardiac events in patients randomized to OMT alone versus "FFR-guided PCI plus OMT". The board concluded that this difference was highly unlikely to change with the enrollment of additional patients.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from
About
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from
About Zacks
Zacks.com is a property of
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
SOURCE